Abstract
Purpose
While the spectrum of germline mutations in BRCA1/2 genes in the Israeli Jewish population has been extensively studied, there is a paucity of data pertaining to Israeli Arab high-risk cases.
Methods
Consecutive Israeli Arab breast and/or ovarian cancer patients were recruited using an ethically approved protocol from January 2012 to February 2019. All ovarian cancer cases were referred for BRCA genotyping. Breast cancer patients were offered BRCA sequencing and deletion/duplication analysis after genetic counseling, if the calculated risk for carrying a BRCA mutation by risk prediction algorithms was ≥10%.
Results
Overall, 188 patients participated; 150 breast cancer cases (median age at diagnosis: 40 years, range 22–67) and 38 had ovarian cancer (median age at diagnosis: 52.5 years, range 26–79). Of genotyped cases, 18 (10%) carried one of 12 pathogenic or likely-pathogenic variants, 12 in BRCA1, 6 in BRCA2. Only one was a rearrangement. Three variants recurred in more than one case; one was detected in five seemingly unrelated families. The detection rate for all breast cancer cases was 4%, 5% in bilateral breast cancer cases and 3% if breast cancer was diagnosed < 40 years. Of patients with ovarian cancer, 12/38 (32%) were carriers; the detection rate reached 75% (3/4) among patients diagnosed with both breast and ovarian cancer.
Conclusions
The overall yield of comprehensive BRCA1/2 testing in high-risk Israeli Arab individuals is low in breast cancer patients, and much higher in ovarian cancer patients. These results may guide optimal cancer susceptibility testing strategy in the Arab–Israeli population.
Similar content being viewed by others
References
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62:676–689
Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S et al (2017) NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw 15:9–20
Karami F, Mehdipour P (2013) A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013:928562. https://doi.org/10.1155/2013/928562
The Central Bureau of Statistics. https://www.cbs.gov.il/en/subjects/Pages/Population.aspx. Accessed 16 Mar 2019
Spencer C. Tucker; Priscilla Roberts (12 May 2008). The Encyclopedia of the Arab-Israeli Conflict: A Political, Social, and Military History [4 volumes]: A Political, Social, and Military History. ABC-CLIO. p. 503. ISBN 978-1-85109-842-2
Al-Kuraya K, Schraml P, Sheikh S, Amr S, Torhorst J, Tapia C et al (2005) Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol 18:891–897
Atoum MF, Al-Hourani HM (2004) Lifestyle related risk factors for breast cancer in Jordanian females. Saudi Med J 25:1245–1248
CI5 - Home [Internet]. Cancer Incid. Five Cont. Vol X Electron. Version. http://ci5.iarc.fr/Default.aspx. Accessed 15 Oct 2018
Bener A, Ayub H, Kakil R, Ibrahim W (2008) Patterns of cancer incidence among the population of qatar: a worldwide comparative study. Asian Pac J Cancer Prev 9:19–24
El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F et al (2007) Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 5:225–233
Mahfoudh W, Bouaouina N, Ahmed SB, Gabbouj S, Shan J, Mathew R et al (2012) Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep 39:1037–1046
Lolas Hamameh S, Renbaum P, Kamal L, Dweik D, Salahat M, Jaraysa T et al (2017) Genomic analysis of inherited breast cancer among Palestinian women: genetic heterogeneity and a founder mutation in TP53. Int J Cancer 141:750–756
Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M et al (2011) Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Treat 127:489–495
Zidan J, Zhou AY, van den Akker J, Laitman Y, Schayek H, Schnaider J et al (2017) Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel. Breast Cancer Res Treat 166:881–885
Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158
The Penn II Risk Model, BRCA 1 and BRCA 2 Mutation Predictor [Internet]. https://pennmodel2.pmacs.upenn.edu/penn2/index.jsp. Accessed 2 Sep 2017
BRCA Calculator [Internet]. http://www.myriadpro.com/brca-risk-calculator/calc.html. Accessed 7 Sep 2017.
Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N et al (2018) The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Res Treat 172:151–157
Jalkh N, Nassar-Slaba J, Chouery E, Salem N, Uhrchammer N, Golmard L et al (2012) Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon. Hered Cancer Clin Pract 10:7
El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM et al (2015) BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. Oncologist 20:357–364
Abdel-Razeq H, Al-Omari A, Zahran F, Arun B (2018) Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer 18:152
Cintolo-Gonzalez JA, Braun D, Blackford AL, Mazzola E, Acar A, Plichta JK et al (2017) Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Res Treat 164:263–284
Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H et al (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807–2816
Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Napoli MD et al (2019) PARP inhibitors in ovarian cancer. Cancer Treat Rev 73:1–9
Menéndez M, Castellsagué J, Mirete M, Pros E, Feliubadaló L, Osorio A et al (2012) Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 132:979–992
Farra C, Dagher C, Badra R, Hammoud MS, Alameddine R, Awwad J et al (2019) BRCA mutation screening and patterns among high-risk Lebanese subjects. Hered Cancer Clin Pract 17:4. https://doi.org/10.1186/s13053-019-0105-9
Quiles F, Teulé À, Martinussen Tandstad N, Feliubadaló L, Tornero E, del Valle J et al (2016) Identification of a founder BRCA1 mutation in the Moroccan population. Clin Genet 90:361–365
Online Research Resources Developed at NHGRI [Internet]. Online Res. Resour. Dev. NHGRI. https://research.nhgri.nih.gov/. Accessed 15 Oct 2018
Kadouri L, Bercovich D, Elimelech A, Lerer I, Sagi M, Glusman G et al (2007) A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer. BMC Cancer 7:14
Paperna T, Sharon-Shwartzman N, Kurolap A, Goldberg Y, Moustafa N, Carasso Y et al (2019) Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype. J Med Genet. https://doi.org/10.1136/jmedgenet-2018-105824
Zick A, Kadouri L, Cohen S, Frohlinger M, Hamburger T, Zvi N et al (2017) Recurrent TP53 missense mutation in cancer patients of Arab descent. Fam Cancer 16:295–301
Goldberg Y, Barnes-Kedar I, Lerer I, Halpern N, Plesser M, Hubert A et al (2015) Genetic features of Lynch syndrome in the Israeli population. Clin Genet 87:549–553
Abu Freha N, Leibovici Weissman Y, Fich A, Barnes Kedar I, Halpern M, Sztarkier I et al (2018) Constitutional mismatch repair deficiency and Lynch syndrome among consecutive Arab Bedouins with colorectal cancer in Israel. Fam Cancer 17:79–86
Baris HN, Barnes-Kedar I, Toledano H, Halpern M, Hershkovitz D, Lossos A et al (2016) Constitutional mismatch repair deficiency in Israel: high proportion of founder mutations in MMR genes and consanguinity. Pediatr Blood Cancer 63:418–427. https://doi.org/10.1002/pbc.25818
Funding
This study was not funded by any grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the IRB in the participating institutions.
Informed consent
As data were aggregative and anonymous no informed consent was required by the institutional IRB.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bernstein-Molho, R., Barnes-Kedar, I., Ludman, M.D. et al. The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. Breast Cancer Res Treat 178, 231–237 (2019). https://doi.org/10.1007/s10549-019-05379-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-019-05379-6